Publication | Closed Access

Public funding of new cancer drugs: Is NICE getting nastier?

Preventive MedicineHealth PolicyHealth EconomicsMedicineCancer ManagementPharmacoeconomicsOrphan DrugPublic FundingCancer TreatmentPublic Health PolicyPublic HealthOncologyCancer EducationCancer Research